After quantifying IGF-II and H19 mRNA expression in the PrEvENT cohort, we utilised the cBioPortal for Cancer Genomics website to assess whether co-expression of IGF-II and H19 mRNA existed, in a larger prostate cancer cohort, as well as another hormone-responsive cancer type: breast. The gene discussed is IGF2; the disease is prostate carcinoma.